Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.50−0.17 (-1.59%)
Close on Nov 18, 2026Market cap $8.38BP/E –Yield –
Summit Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Summit Therapeutics's operating income for the twelve months ending Dec 31, 2024 was -$226.00M. For fiscal 2024 it was -$226.00M. The highest annual figure on record is $5.39M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$226.00M | – |
| FY2023 | Dec 31, 2023 | -$609.65M | – |
| FY2022 | Dec 31, 2022 | -$72.09M | – |
| FY2021 | Dec 31, 2021 | -$86.19M | -1699.3% |
| FY2019 | Jan 31, 2019 | $5.39M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$65.61M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$58.38M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$59.62M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$42.39M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$36.21M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$20.49M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$15.79M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$537.15M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$20.30M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$16.94M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$12.69M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$22.16M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$26.05M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$19.49M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$23.73M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$16.92M | – |
See a number that looks wrong?